P

Inventor

KLEIN LAWRENCE

US37 patents
⚠️ This page may combine multiple inventors who share the name “KLEIN LAWRENCE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

CRISPR THERAPEUTICS AG

19 patents
US10736919B2Aug 11, 2020

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG13 citations94
US11071755B1Jul 27, 2021

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG7 citations92
US10881689B2Jan 5, 2021

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG7 citations92
US10857184B2Dec 8, 2020

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG9 citations92
US10729725B2Aug 4, 2020

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG7 citations92
US11166985B2Nov 9, 2021

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG10 citations86
US11298378B2Apr 12, 2022

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG2 citations84
US11207351B2Dec 28, 2021

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG3 citations84
US11202802B2Dec 21, 2021

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG2 citations84
US11191783B2Dec 7, 2021

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG6 citations84
US11135247B2Oct 5, 2021

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG6 citations84
US11013767B2May 25, 2021

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG5 citations84
US11559588B2Jan 24, 2023

Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders

CRISPR THERAPEUTICS AG12 citations83
US11622977B2Apr 11, 2023

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG1 citations73
US11471491B1Oct 18, 2022

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG1 citations73
US11174469B2Nov 16, 2021

Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders

CRISPR THERAPEUTICS AG1 citations60
US11920148B2Mar 5, 2024

Compositions and methods for gene editing

CRISPR THERAPEUTICS AG0 citations57
US11564997B2Jan 31, 2023

Materials and methods for treatment of friedreich ataxia and other related disorders

CRISPR THERAPEUTICS AG0 citations50
US11407997B2Aug 9, 2022

Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders

CRISPR THERAPEUTICS AG0 citations50

ECONOMIC ALCHEMY INC

7 patents

VERTEX PHARMA

4 patents

OUTRIDER TECH INC

3 patents

Economic Alchemy LLC

1 patent

IMX INC

1 patent

KLEIN LAWRENCE

1 patent

ORACLE INT CORP

1 patent